Press Releases
- Clinical safety and preclinical ocular biodistribution for laquinimod eye drops presented at the IOIS meeting available at Active Biotech’s website
- Tasquinimod successfully completes dose optimization in patients with multiple myeloma and advances into the pre-planned expansion cohort
- Active Biotech Interim Report Q2 2023
- Active Biotech enters into clinical trial collaboration agreement for a clinical study with tasquinimod in myelofibrosis
- Safety and ocular biodistribution support development of laquinimod eye drops for inflammatory eye disorders